ProCE Banner Activity


From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC


Watch this on-demand webcast featuring expert presentations and discussion on novel agents targeting HER3 in EGFR TKI-resistant NSCLC, including scientific rationale and new trial data.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 05, 2023

Expiration: June 04, 2024

No longer available for credit.



Yasushi Goto

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Target Audience

This program is intended for medical oncologists and other healthcare providers who care for patients with lung cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate the most recent and emerging data on HER3-targeting agents into NSCLC treatment paradigms.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the biologic rationale for targeting HER3 and its role in the resistance to EGFR-directed therapies

  • Appraise new and emerging clinical trial data assessing HER3-targeting agents in NSCLC 

  • Describe to colleagues the therapeutic rationale for HER3-targeting and TKI combination therapy in EGFR-mutated NSCLC

  • Select patients with NSCLC who may benefit from ongoing clinical trials evaluating HER3-directed therapies based on tumor characteristics, previous treatment, and patient characteristics and preferences


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Yasushi Goto, MD, PhD: consultant/advisor/speaker: Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Merck, MSD, Novartis, Ono, Pfizer, Thermo Fisher; research grants (paid to institution): AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Kyorin, Novartis, Ono, Pfizer, Preferred Network; research grants (paid to clinical trial group): AZK, Pfizer; advisory board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Guardant Health, Illumina, Lilly, MSD, Novartis, Ono, Pfizer, Taiho.

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Blueprint, Daiichi Sankyo, Janssen, Taiho.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 05, 2023, through June 04, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.